Terray Therapeutics
Combines ultra high throughput chemical synthesis with AI to find small molecules.
What they do
Terray Therapeutics integrates massive physical chemical experimentation with generative artificial intelligence. Their proprietary platform generates vast biochemical datasets to design and optimize novel small molecule therapeutics for hard to target diseases.
The record
- Vertical
- Pharma & Drug Discovery
- Sub-segment
- AI drug discovery
- Product type
- Platform software
- Stage
- Series B
- Headquarters
- Pasadena, United States
- Region
- North America
- Founded
- 2018
- Total funding
- $200M raised
Notable investors: Madrona, Two Sigma Ventures, F-Prime Capital, Goldman Sachs Asset Management.